RT Journal Article
SR Electronic
T1 Marburg Virus Disease outbreaks, mathematical models, and disease parameters: a Systematic Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.10.23292424
DO 10.1101/2023.07.10.23292424
A1 Cuomo-Dannenburg, Gina
A1 McCain, Kelly
A1 McCabe, Ruth
A1 Unwin, H. Juliette T.
A1 Doohan, Patrick
A1 Nash, Rebecca K.
A1 Hicks, Joseph T.
A1 Charniga, Kelly
A1 Geismar, Cyril
A1 Lambert, Ben
A1 Nikitin, Dariya
A1 Skarp, Janetta
A1 Wardle, Jack
A1 ,
A1 Kont, Mara
A1 Bhatia, Sangeeta
A1 Imai, Natsuko
A1 van Elsland, Sabine
A1 Cori, Anne
A1 Morgenstern, Christian
YR 2023
UL http://medrxiv.org/content/early/2023/07/12/2023.07.10.23292424.abstract
AB Background Recent Marburg virus disease (MVD) outbreaks in Equatorial Guinea and Tanzania highlighted the importance of better understanding this highly lethal infectious pathogen. Past epidemics of Ebola, COVID-19, and other pathogens have re-emphasised the usefulness of mathematical models in guiding public health responses during outbreaks.Methods We conducted a systematic review, registered with PROSPERO (CRD42023393345) and reported according to PRISMA guidelines, of peer-reviewed papers reporting historical out-breaks, modelling studies and epidemiological parameters focused on MVD, including contextual information. We searched PubMed and Web of Science until 31st March 2023. Two reviewers evaluated all titles and abstracts, with consensus-based decision-making. To ensure agreement, 31% (13/42) of studies were double-extracted and a custom-designed quality assessment questionnaire was used to assess the risk of bias.Findings We present detailed outbreak, model and parameter information on 970 reported cases and 818 deaths from MVD until 31 March 2023. Analysis of historical outbreaks and sero-prevalence estimates suggests the possibility of undetected MVD outbreaks, asymptomatic transmission and/or cross-reactivity with other pathogens. Only one study presented a mathematical model of MVD transmission. We estimate an unadjusted, pooled total random effect case fatality ratio for MVD of 61.9% (95% CI: 38.8-80.6%, I2=93%). We identify key epidemiological parameters relating to transmission and natural history for which there are few estimates.Interpretation This review provides a comprehensive overview of the epidemiology of MVD, identifying key knowledge gaps about this pathogen. The extensive collection of knowledge gathered here will be crucial in developing mathematical models for use in the early stages of future outbreaks of MVD. All data are published alongside this article with functionality to easily update the database as new data become available.Funding MRC Centre for Global Infectious Disease AnalysisResearch in ContextEvidence before this studyWe searched Web of Science and PubMed up to 31 March 2023 using the search terms Marburg virus, epidemiology, outbreaks, models, transmissibility, severity, delays, risk factors, mutation rates and seroprevalence. We found five systematic reviews, all of which considered MVD alongside Ebola virus disease (EVD). One modelling study of Marburg virus disease (MVD) focused on animals, and not on computational models to understand past or project future disease transmission. One systematic review collated risk factors for transmission based on four MVD studies, but did not report attack rates due to missing underlying MVD estimates; another systematic review pooled estimates of MVD case fatality ratios (CFR): 53.8% (95% CI: 26.5–80.0%) and seroprevalence: 1.2% (95% CI: 0.5–2.0%). No systematic review covered transmission models of MVD, and the impact of public health and social measures is unknown.Added value of this studyWe provide a comprehensive summary of the available, peer-reviewed literature of historical outbreaks, transmission models and parameters for MVD. Meta-analysis of existing estimates of CFRs, and our original estimates based on historical outbreak information, illustrate the severity of MVD with our pooled random effect estimated CFR of 61.9% (95% CI: 38.8-80.6%, I2=93%). We demonstrate the sparsity of evidence on MVD transmission and disease dynamics, particularly on transmissibility and natural history, which are key input parameters for computational models supporting outbreak response. Our work highlights key areas where further disease characterization is necessary.Implications of all the available evidencePrevious outbreaks of infectious pathogens emphasized the usefulness of computational modelling in assessing epidemic trajectories and the impact of mitigation strategies. Our study provides necessary information for using mathematical models in future outbreaks of MVD, identifies uncertainties and knowledge gaps in MVD transmission and natural history, and highlights the severity of MVD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1) jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; the National Institute for Health Research (NIHR) for support for the Health Research Protection Unit for Modelling and Health Economics, a partnership between UK Health Security Agency, Imperial College London and London School of Hygiene & Tropical Medicine (LSHTM) (grant code NIHR200908). Additional individual funding sources: CM acknowledges the Schmidt Foundation for research funding (grant code 6-22-63345); PD acknowledges funding by Community Jameel; GCD acknowledges funding from the Royal Society; RM acknowledges the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections, a partnership between PHE, University of Oxford, University of Liverpool and Liverpool School of Tropical Medicine (grant code NIHR200907); JW acknowledges research funding from the Wellcome Trust (grant 102169/Z/13/Z); RKN acknowledges research funding from the Medical Research Council (MRC) Doctoral Training Partnership (grant MR/N014103/1); JS acknowledges research funding from the Wellcome Trust (grant 215163/Z/18/Z); KM acknowledges research funding from the Imperial College President PhD Scholarship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://github.com/mrc-ide/epireview